Edgestream Partners L.P. Buys New Shares in Charles River Laboratories International, Inc. $CRL

Edgestream Partners L.P. purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 9,036 shares of the medical research company’s stock, valued at approximately $1,559,000.

Other hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $42,000. Sfam LLC bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $43,000. Activest Wealth Management increased its holdings in Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $46,000. Finally, Geneos Wealth Management Inc. raised its position in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. Morgan Stanley increased their target price on Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a research report on Friday, May 8th. Finally, Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $220.75.

Charles River Laboratories International Stock Down 0.8%

CRL stock opened at $230.58 on Tuesday. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $242.73. The business has a 50-day simple moving average of $207.99 and a 200 day simple moving average of $188.00. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market cap of $11.11 billion, a PE ratio of -61.33, a price-to-earnings-growth ratio of 2.59 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same period last year, the firm earned $2.34 EPS. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.